期刊文献+

联合用药对阿立哌唑及其代谢物血药浓度的影响 被引量:1

Effect of Drug Combination on Blood Concentration of Aripiprazole and Its Metabolite
原文传递
导出
摘要 目的:考察联合用药对阿立哌唑(ARI)及其代谢物脱氢阿立哌唑(DARI)血药浓度的影响。方法:采集我中心2010年1月-2011年3月血药浓度临床检测数据库中服用ARI(包括联合用药)治疗的住院患者信息,入组231例,单独服用ARI者79例作为对照组,合并用药者152例。对13种精神科常用药对ARI及其代谢物血药浓度的影响进行分析。血药浓度测定采用高效液相色谱法,数据统计分析利用SPSS 13.0软件进行。结果:ARI合用丙戊酸钠、利培酮等治疗时,相比于对照组其剂量调节血药浓度(Concentration to dose ratios,C∶D比率,nmol·L-1·mg-1)分别降低了约17.6%(P=0.36)、24.2%(P=0.19),但组间比较差异无统计学意义;合用喹硫平,其C∶D比率降低了约30.1%,组间比较差异有统计学意义;合用文拉法辛、氯氮平等对ARI及DARI的血药浓度无显著性影响。结论:联合用药对ARI血药浓度有不同程度的影响,而对DARI浓度则无明显影响。在临床用药中,应考虑药物间的相互作用,适当调整剂量,以达到有效治疗结果。 OBJECTIVE: To investigate the effect of drug combination on blood concentration of aripiprazole (ARI) and its metabolite dehydroaripiprazole (DARI). METHODS: The information of 231 inpatients receiving ARI (including drug combination) was collected from blood concentration clinical monitoring database of our center from Jan. 2010 to Mar. 2011. 152 inpatients received drug combination, and the remaining 79 was given ARI alone(control group). The effects of 13 kinds of common antipsychotics drugs on ARI and its metabolite were analyzed. Blood concentrations of them were determined by HPLC, and data analysis was conducted by SPSS 13.0 software. RESULTS: Compared with control group, blood concentration of ARI (concentration to dose ratios, ratio of C to D, nmol·L^-1·mg^-1) in ARI combined with valproate group and risperidone group decreased by 17.6% (P=0.36) and 24.2% (P=0.19) approximately, there was no statistical significance. Ratio of C to D in ARI combined with quetiapine decreased by 30.1%, there was statistical significance. ARI combined with venlafaxine and clozapine had no significant effect on the blood concentration of ARI and DARI. CONCLUSION: Drug combination affects the blood concentration of ARI at different levels, but has no evident effect on the blood concentration of DARI. In the clinical practice, drug interactions should be considered and the dose should be adjusted to achieve an active result.
出处 《中国药房》 CAS CSCD 北大核心 2011年第42期3968-3970,共3页 China Pharmacy
基金 国家重点基础研究发展计划(2007CB512306) 上海市精神卫生中心院级课题(2009-YJ-11)
关键词 阿立哌唑 脱氢阿立哌唑 血药浓度 联合用药 Aripiprazole Dehydroaripiprazole Blood concentration Drug combination
  • 相关文献

参考文献11

  • 1张晓红,白延.简述新型抗精神病药阿立哌唑[J].四川精神卫生,2006,19(4):258-259. 被引量:5
  • 2Waade RB, Christensen H, Rudberg I, et al. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole[J] .Ther Drug Monit, 2009,31 (2) : 233.
  • 3Citrome L, Josiassen R, Bark N, et al.Pharmacokinetics of aripiprazole and concomitant lithium and valproate[J]. J Clin Pharmacol, 2005,45 (1) :89.
  • 4Citrome L, Josiasson R, Bark N, et al.Pharmacokineties and safety of Aripiprazole and concomitant mood stabilizers [J].Int J Neuropsychopharmazol, 2002,5 ( Suppl 1 ) : 5 257.
  • 5Castberg I, Spigset O.Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service[J]. Pharmacopsychiatry, 2007,40 (3): 107.
  • 6Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile[J].Clin Pharmacokinet, 1999,37 (3) : 177.
  • 7Linnet K.Glucuronidation of olanzapine by eDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes[J]. Hum Psychopharmacol, 2002,17 (5) : 233.
  • 8Rowland A, Elliot DJ, Williams JA, et al.In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction[J]. Drug Metab Dispos,2006,34(6):1 055.
  • 9周志凌,李焕德.非典型抗精神病药利培酮的药代动力学研究进展[J].中国临床药理学杂志,2004,20(3):228-233. 被引量:14
  • 10Suzuki T, Mihara K, Nakamura A, et al.Effects of the CYP2D6*10 Allele on the steady-state plasma concentra- tions of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia[J]. Ther Drug Monit , 2011, 33 (1) :21.

二级参考文献32

  • 1李海林 谢世平 等.不同剂量的利培酮治疗精神分裂症的临床观察[J].中国新药杂志,1999,8(3):183-185.
  • 2[1]Bhana N, Spencer CM. Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia[J]. Drugs Aging, 2000; 16:451-471.
  • 3[2]De Coster R, Doolaege R, Heylen S, et al. Effects of single oral and intramuscular administrations of risperidone on plasma prolactin,growth hormone, thyrotropin,T3 and cortisol in healthy male volunteer[J]. Clin Res Report, 1988.
  • 4[3]Byerly MJ, Devane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature[J]. Clin Psychopharmacol Copyright, 1995;26:177-187.
  • 5[4]Heykants J, Huang ML, Mannens G, et al. The Pharmacokinetics of risperidone in humans: a summary[J]. J Clin Psychiatry, 1994;55(Suppl.):S 13-S 18.
  • 6[5]Ershefsky L, Lacombe S. Pharmacological profile of risperidone[J]. Can J Psychinatry, 1993;38:80-88.
  • 7[6]Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4[J]. Naunyn Schmiedebergs Arch Pharmacol, 1999;359:147-151.
  • 8[7]Yasui-Furukori N, Hidestrand M, Spina E, et a/.Differentenantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes[J]. Drug Metab Dispos, 2001;29:1263-1268.
  • 9[9]Roh HK, Kim CE, Chung WG, et al. Risperidone metabolism in relation to CYP2D6* 10 allele in Korean schizophrenic patients[J]. Eur J Clin Pharmacol, 2001 ;57:671-675.
  • 10[10]Scordo MG, Spina E, Facciola G, et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone[J]. Psychopharmacology, 1999;147:300-305.

共引文献17

同被引文献1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部